Organic Revenue Growth
Total company organic revenue growth, which excludes currency and acquisition effects, was 9.0% in Q2 FY2026, with CAG organic growth at 8.7% and Water at 13.0%.
IDEXX LABORATORIES INC /DE is expected to release its Q3 2026 10-Q filing on November 2, 2026, before market open. Last quarter: IDEXX Laboratories posted higher Q2 FY2026 revenue and net income, led by strong CAG diagnostics recurring sales and broad margin improvement.
EPS Estimate
$3.85
Revenue Estimate
$1.22B
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the IDXX page.
Drawn from management commentary in the Q2 2026 10-Q:
Total company organic revenue growth, which excludes currency and acquisition effects, was 9.0% in Q2 FY2026, with CAG organic growth at 8.7% and Water at 13.0%.
CAG instrument revenue fell 19.5% reported, primarily due to lower placements of the IDEXX inVue Dx Analyzer compared to its broad commercial availability in the second quarter of 2025.
The 140-basis-point increase in consolidated gross margin to 64.0% reflected higher-margin consumable and lab volume growth, lower premium instrument mix, operational productivity, and net price realization.
Revenue
$1.22B
+9.66% YoY
EPS (Diluted)
$4.27
+17.63% YoY
Gross Margin
64.0%
+1.4 pts YoY
Operating Income
$425.57M
+14.08% YoY
Add IDXX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.